-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Globally, about 292 million people have been or are infected with the hepatitis B virus (HBV);
Chronic HBV infection can cause fibrosis and eventually develop into hepatocellular carcinoma, and the assessment of serum alanine amino transferase (ALT) levels is a relatively inexpensive biotransviral test that is widely used to detect liver damage.
, however, recent evidence suggests that some patients with ALT can also develop severe liver fibrosis normally.
biopsy (LB) is the gold standard for diagnosing liver fibrosis.
, however, there is a risk of postoperative complications, and serum copper blue protein (CP) is a glycoprotein secreted by liver cells that carries more than 95% of circulating copper in healthy people.
studies have shown that CP has strong antioxidant function and prohibits the display of lipid peroxidation.
previous data showed a negative correlation between CP and liver fibrosis, suggesting that CP was a useful marker for diagnosing liver fibrosis.
reviewed 275 people infected with HBV.
statistical analysis of the association between CP and fibrosis stages.
predictive indicators, including CP (Copper Blue Protein Hepatitis B Virus (CPHBV), were constructed to predict significant fibrosis and compared with previously reported models.
results showed a negative correlation between serum CP and liver fibrosis (r - -0.600).
CP to predict severe fibrosis, late fibrosis and liver cirrhosis with a curved area (AUC) of 0.774, 0.812 and 0.853, respectively.
developed CPHBV models using CP, plateplate (PLT) and HBsAg levels to predict significant fibrosis.
model predicts severe fibrosis, with AAUCs for late fibrosis and cirrhosis at 0.842, 0.920 and 0.904, respectively.
CPHBV is superior to the AST to PLT ratio index in predicting significant fibrosis of HBV infection.
, the researchers say the CPHBV score, built by CP, can accurately predict the level of liver fibrosis in individual patients infected with HBV.
.
